Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SnowWorld N.V. Earnings Release 2008

Mar 12, 2009

3886_iss_2009-03-12_d7d02adb-238b-42de-980c-6e035c5cf808.pdf

Earnings Release

Open in viewer

Opens in your device viewer

APPENDIX TO PRESS RELEASE 12 MARCH 2009

Fornix BioSciences N.V.

Fornix BioSciences N.V. appendix to press release 12 March 2009 1

CONSOLIDATED INCOME STATEMENT

for the financial year from 1 January 2008 to 31 December 2008 with comparative figures for the 2007 financial year

2008 2007
business
20071)
Continued Discontinued
business
2007
Total activities activities Total
Income 39,826 38,093 46,636 84,729
Cost of sales 6,951 6,607 44,084 50,691
Gross result 32,875 31,486 2,552 34,038
Other Income 216 112 2,078 2,190
Distribution costs 1,561 1,413 119 1,532
Personnel costs 8,130 7,249 1,228 8,477
Travel expenses 1,333 1,235 56 1,291
Depreciation and amortisation 471 499 183 682
Accommodation costs 308 225 23 248
Research and development costs 5,830 4,054 - 4,054
Quality control costs 342 385 162 547
Production and warehouse costs 142 142 35 177
General overheads 3,765 2,599 657 3,256
Charged on to production and
trading inventories (1,425) (1,468) (3) (1,471)
Sum of the costs 20,457 16,333 2,460 18,793
Result from operating
activities
12,634 15,265 2,170 17,435
Net financing income/expenses 1,296 1,074 (253) 821
Profit before taxation 13,930 16,339 1,917 18,256
Tax on profits 3,665 4,312 (37) 4,275
Profit for the financial year 10,265 12,027 1,954 13,981
2008 2007
business
20071)
Continued Discontinued
business
2007
Total activities activities Total
Attributable to:
Shareholders of the
parent company 10,265 12,027 1,954 13,981
Minority interest - - - -
Profit for the financial year 10,265 12,027 1,954 13,981
Ordinary earnings per share (in €) 1.39 1.73 0.28 2.01
Diluted earnings per share (in €) 1.39 1.73 0.28 2.01

1) The 2007 justified discontinued business activities are the result of the sale of the Trading Division in the year 2007.

CONSOLIDATED SUMMARY OF TOTAL RESULT

for the financial year from 1 January 2008 to 31 December 2008 with comparative figures for the 2007 financial year

2008 2007
Exercise of personnel options 475 211
Net profit directly accounted for in the shareholders' equity 475 211
Profit for the financial year 10,265 13,981
Total result for the financial year 10,740 14,192
Attributable to:
Shareholders of the parent company 10,740 14,192
Minority interest - -
Total result for the financial year 10,740 14,192

CONSOLIDATED BALANCE SHEET

(before allocation of the result)

as at 31 December 2008 with comparative figures as at 31 December 2007

31 December 2008 31 December 2007
ASSETS
Non-current assets
Intangible assets 13,750 12,904
Property, plant and equipment 3,054 3,036
Deferred tax assets 80 128
Total Non-current assets 16,884 16,068
Current assets
Inventories 3,746 3,347
Trade and other receivables 7,747 6,537
Cash and cash equivalents 32,021 33,235
Total Current assets 43,514 43,119
Total Assets 60,398 59,187
LIABILITIES AND EQUITY
Shareholders' equity
Paid-up and called-up share capital 1,157 1,089
Share premium 32,896 27,016
Other reserves 7,594 7,121
Profit for the financial year 10,265 13,981
Total Shareholders' equity attributable to shareholders 51,912 49,207
of the parent company
Minority interest 1 1
Total Shareholders' equity 51,913 49,208
Non-current liabilities
Employee benefits 38 192
Deferred tax liabilities 259 239
Total Non-current liabilities 297 431
Current liabilities
Provisions - 35
Trade payables 2,571 2,475
Taxes payable 308 454
Other items to be paid 5,309 6,584
Total Current liabilities 8,188 9,548
Total Liabilities and equity 60,398 59,187

CONSOLIDATED CASH FLOW STATEMENT

for the financial year from 1 January 2008 to 31 December 2008 with comparative figures for the 2007 financial year

2008 2007
Cash flow from operating activities
Receipts from customers 41,570 88,617
Payments to suppliers and employees (29,118) (77,291)
Net cash flow from business operations 12,452 11,326
Interest received 726 711
Interest paid (3) (4)
Tax paid on profits (3,355) (4,595)
Grants received 15 65
Cash flow from other operating activities (2,617) (3,823)
Net cash flow from operating activities 9,835 7,503
Cash flow from investing activities
Acquisition of subsidiaries (1,299) (2,050)
Acquisition activities DeCube®
products
(1,250) -
Investments in intangible assets (32) (120)
Investments in property, plant and equipment (422) (165)
Divestment in subsidiaries - 13,080
Net cash flow from investing activities (3,003) 10,745
Cash flow from financing activities
Earnings from exercise of staff options 476 211
Dividend paid (8,525) (6,042)
Net cash flow from financing activities (8,049) (5,831)
Net decrease / increase in cash and cash equivalents (1,217) 12,417
Cash and cash equivalents as at 1 January 33,235 20,749
Cash acquired subsidiaries 3 74
Assignment from divestments - (5)
Cash and cash equivalents as at 31 December 32,021 33,235

CHANGES IN SHAREHOLDERS' EQUITY

Balance as at 1 January 2007 40,505
Dividend payment 2006 (3,611)
Interim dividend 2007 (2,431)
Profit for 2007 financial year 13,981
Exercise of personnel options 211
Cost of share ownership plan 2007 552
Balance as at 31 December 2007 49,207
Dividend payment 2007 (5,022)
Interim dividend 2008 (3,503)
Profit for 2008 financial year 10.265
Exercise of personnel options 476
Issue of shares in the context of the share ownership plan 2008 2
Cost of share ownership plan 2008 487
Balance as at 31 December 2008 51,912

Notes

1 General

The financial data as reported in this press release are an excerpt from the annual accounts of Fornix BioSciences N.V. (the 'Company') but do not represent the full annual accounts. The Company's consolidated annual accounts for 2008 include the Company and its subsidiaries (together referred to as the "Group").

The annual report and annual accounts were discussed in the supervisory Board meeting of 9 March 2009 and will be submitted to the Annual General Meeting of shareholders for adoption on 24 April 2009. The auditors of Fornix BioSciences N.V. have issued an unqualified opinion on these annual accounts.

Publication of the full annual accounts 2008 will be available at the latest on 9 April 2009.

2 Statement of compliance

The annual accounts 2008 have been prepared in accordance with International Financial Reporting Standards (IFRSs), as adopted by the European Union.

3 Basis of preparation

The consolidated annual accounts are presented in thousands of euros.

The Group reports according to IFRS. For the year 2008 no important changes occurred with regard to the accounting principles of the Group.

4 Use of estimates and judgements

The preparation of the annual accounts requires the management of the Company to form opinions and to make estimates and assumptions that influence the application of policies and the reported values of assets and liabilities and of income and expenses. The actual outcomes may differ from these estimates.